6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02174250 (ClinicalTrials.gov)	June 2014	24/6/2014	The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.	Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy Subjects	Parkinson's Disease	Drug: Istradefylline 40 mg;Drug: Rifampin 300mg BID + istradefylline 40mg Day 8 only	Kyowa Hakko Kirin Pharma, Inc.	NULL	Completed	18 Years	65 Years	Both	20	Phase 1	United States
2	NCT01968031 (ClinicalTrials.gov)	October 2013	18/10/2013	A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease	A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: Istradefylline 40 mg;Drug: Istradefylline 20 mg;Drug: Placebo	Kyowa Hakko Kirin Pharma, Inc.	Kyowa Kirin Co., Ltd.	Completed	30 Years	N/A	All	613	Phase 3	United States;Canada;Czechia;Germany;Israel;Italy;Poland;Serbia;Czech Republic